ID   MG63.2
AC   CVCL_R705
DR   Wikidata; Q54905421
RX   PubMed=19363654;
RX   PubMed=26320182;
CC   Doubling time: 36.1 hours (PubMed=19363654).
CC   Sequence variation: Homozygous for CDKN2A deletion (from parent cell line).
CC   Omics: Transcriptome analysis.
DI   NCIt; C9145; Osteosarcoma
DI   ORDO; Orphanet_668; Osteosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0426 ! MG-63
SX   Male
AG   14Y
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 12-03-20; Version: 9
RX   PubMed=19363654; DOI=10.1007/s10585-009-9259-6;
RA   Su Y.-X., Luo X.-J., He B.-C., Wang Y., Chen L., Zuo G.-W., Liu B.,
RA   Bi Y., Huang J.-Y., Zhu G.-H., He Y., Kang Q., Luo J.-Y., Shen J.-K.,
RA   Chen J., Jin X.-Q., Haydon R.C., He T.-C., Luu H.-H.;
RT   "Establishment and characterization of a new highly metastatic human
RT   osteosarcoma cell line.";
RL   Clin. Exp. Metastasis 26:599-610(2009).
RX   PubMed=26320182; DOI=10.18632/oncotarget.5177;
RA   Ren L., Mendoza A., Zhu J., Briggs J.W., Halsey C., Hong E.S.,
RA   Burkett S.S., Morrow J., Lizardo M.M., Osborne T., Li S.Q., Luu H.H.,
RA   Meltzer P.S., Khanna C.;
RT   "Characterization of the metastatic phenotype of a panel of
RT   established osteosarcoma cells.";
RL   Oncotarget 6:29469-29481(2015).